ImmunityBio
IBRX
404 hedge funds and large institutions have $1.77B invested in ImmunityBio in 2026 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 142 increasing their positions, 101 reducing their positions, and 44 closing their positions.
128% more call options, than puts
Call options by funds: $218M | Put options by funds: $95.3M
50% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 44
41% more repeat investments, than reductions
Existing positions increased: 142 | Existing positions reduced: 101
30% more capital invested
Capital invested by funds: $1.36B → $1.77B (+$410M)
5% more funds holding
Funds holding: 386 → 404 (+18)
1.91% more ownership
Funds ownership: 17.38% → 19.28% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$58.6M |
| 2 |
Two Sigma Investments
New York
|
+$50.8M |
| 3 |
Millennium Management
New York
|
+$31.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$27.9M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$29.7M |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$11.2M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$9.13M |
| 4 |
Barclays
London,
United Kingdom
|
-$8.78M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.43M |
IBRX Hedge Fund Activity: Q2 2026 in Review
404 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2026, worth a combined $1.77B — up 30% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new IBRX positions and 44 closed out — a net gain of 22 holders — while 142 added to existing stakes and 101 trimmed.
The largest buyer was BlackRock, adding an estimated $58.6M. The largest seller was HRT Financial, exiting entirely with an estimated $29.7M sold.
- 404 institutional investors held ImmunityBio (IBRX) as of Q2 2026, up from 386 in Q1 2026.
- Funds reported $1.77B of ImmunityBio stock for Q2 2026, up 30% quarter-over-quarter.
- 66 funds opened new ImmunityBio positions in Q2 2026 and 44 closed out, a net change of +22 holders.
- The largest ImmunityBio buyer in Q2 2026 was BlackRock, an estimated $58.6M added.
- The largest ImmunityBio seller in Q2 2026 was HRT Financial, an estimated $29.7M sold.
Based on aggregated 13F filings for Q2 2026.